Published in Biotech Law Weekly, July 23rd, 2004
The collaboration will use Captisol, a proven technology from CyDex, to develop formulations offering advantages such as improved bioavailability, dissolution, and stability. The companies agreed to develop Captisol-enabled formulations of six drugs initially but, for competitive reasons, did not announce the products.
Hovione's CEO, Guy Villax, commented, "We...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.